A 2018 article by Life Science Leader described Seattle Genetics’ development of “sugar-engineered antibodies,” using proprietary technology that removes 100% of fucose, an essential sugar ...

Addition of fucose to a cell-surface glycoprotein receptor demonstrates the power of glycan engineering to direct homing of adult stem cells to a tissue of choice. Stem cells hold great promise ...

MCLA-145 is under clinical development by Merus and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

Petosemtamab, or MCLA-158, is a Biclonics® low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein ...